Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Oct 21, 2024Journal of affective disorders

Possible links between diabetes drugs called GLP-1 receptor agonists and suicidal thoughts, based on global safety reports

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The reporting odds ratios (ROR) for suicidal ideation were significantly increased for semaglutide (5.82) and liraglutide (4.03).

Significantly increased RORs for suicidal ideation were observed for semaglutide (5.82), liraglutide (4.03), and tirzepatide (2.25).
For the combined category of 'depression/suicidal', semaglutide (14.74) and liraglutide (5.86) showed significantly increased RORs.
Semaglutide (6.52) and liraglutide (3.90) had significantly increased RORs for suicidal behavior.
Significantly decreased RORs were found for suicide attempts with semaglutide (0.11), dulaglutide (0.075), exenatide (0.047), and liraglutide (0.15).
For completed suicide, significantly decreased RORs were noted for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002), and liraglutide (0.008).
Causation between GLP-1 RA exposure and suicidality remains unestablished, as indicated by the mixed patterns in ROR data.

AI simplified

INTRODUCTION: Reports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established.

RESEARCH DESIGN AND METHODS: The analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0.

RESULTS: We searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008).

CONCLUSION: Unlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief